

Amendments to the Claims

**This listing of claims will replace all prior versions and listings of claims.**

1 - 20. Cancelled.

21. (Currently Amended) An isolated human polypeptide comprising an amino acid sequence which is at least 95% identical to a member selected from the group consisting of:

(a) amino acids 1 to 331 of SEQ ID NO:2 or the complete amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 97343;

(b) amino acids 2 to 331 of SEQ ID NO:2 or the complete amino acid sequence excepting the N-terminal methionine encoded by the cDNA clone contained in ATCC Deposit No. 97343;

(c) amino acids 24 to 331 of SEQ ID NO:2;

(d) amino acids 27 to 331 of SEQ ID NO:2; and

(e) the amino acid sequence of the mature form of Neuronal Attachment Factor-1 (NAF-1) encoded by the cDNA clone contained in ATCC Deposit No. 97343;

wherein said polypeptide promotes ~~neuronal cell adhesion or~~ axonal neurite extension of dorsal spinal cord neurons.

22. (Original) The isolated polypeptide of claim 21 wherein said member is (a).

23. (Original) The isolated polypeptide of claim 21 wherein said member is (b).

24. (Original) The isolated polypeptide of claim 21 wherein said member is (c).

25. (Original) The isolated polypeptide of claim 21 wherein said member is (d).

26. (Original) The isolated polypeptide of claim 21 wherein said member is (e).

27. Cancelled.
28. (Original) The isolated polypeptide of claim 21, wherein said polypeptide comprises the amino acid sequence of amino acids 1 to 331 of SEQ ID NO:2.
29. (Original) The isolated polypeptide of claim 21 wherein said polypeptide comprises the complete amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 97343.
30. (Original) The isolated polypeptide of claim 21 wherein said polypeptide comprises the amino acid sequence of amino acids 2 to 331 of SEQ ID NO:2.
31. (Original) The isolated polypeptide of claim 21 wherein said polypeptide comprises the complete amino acid sequence excepting the N-terminal methionine encoded by the cDNA clone contained in ATCC Deposit No. 97343.
32. (Original) The isolated polypeptide of claim 21 wherein said polypeptide comprises the amino acid sequence of amino acids 24 to 331 of SEQ ID NO:2.
33. (Original) The isolated polypeptide of claim 21 wherein said polypeptide comprises the amino acid sequence of amino acids 27 to 331 of SEQ ID NO:2.
34. (Original) The isolated polypeptide of claim 21 wherein said polypeptide comprises the amino acid sequence of amino acids 284 to 330 of SEQ ID NO:2.
35. (Original) The isolated polypeptide of claim 21, wherein said polypeptide comprises the amino acid sequence of the mature form of NAF-1 encoded by the cDNA clone contained in ATCC Deposit No. 97343.
36. (Currently Amended) An epitope-bearing ~~portion~~ fragment of the human NAF-1 polypeptide ~~consisting of wherein said fragment is~~ at least 9 contiguous amino acids of SEQ ID NO:2.

37. (Currently Amended) The epitope-bearing ~~portion~~ fragment of claim 36, ~~which consists of~~ wherein said fragment is at least 15 contiguous amino acids of SEQ ID NO:2.

38 - 42. (Cancelled).

43. (Currently Amended) An isolated polypeptide fragment of the human NAF-1 polypeptide, wherein said fragment is ~~consisting of~~ at least 10 contiguous amino acids of SEQ ID NO:2 and promotes axonal neurite extension of dorsal spinal cord neurons.

44 - 47. (Cancelled).

48. (Currently Amended) The isolated polypeptide of claim 43, ~~which consists of~~ wherein said fragment is at least 30 contiguous amino acids of SEQ ID NO:2.

49. (Currently Amended) The isolated polypeptide of ~~claim 48~~ claim 43, ~~which consists of~~ wherein said fragment is at least of at least 50 contiguous amino acids of SEQ ID NO:2.

50 - 53. (Cancelled).

54. (Original) A fusion protein comprising the isolated polypeptide of claim 21 fused to a heterologous polypeptide.

55. (Currently Amended) A fusion protein comprising the isolated ~~polypeptide~~ epitope bearing fragment of claim 36 fused to a heterologous polypeptide.

56. (Currently Amended) A fusion protein comprising the isolated ~~polypeptide~~ epitope bearing fragment of claim 43 fused to a heterologous polypeptide.

57. (Cancelled).
58. (Previously Amended) A composition comprising the polypeptide of claim 21 and a carrier.
59. (Currently Amended) A composition comprising the ~~polypeptide~~ epitope bearing fragment of claim 36 and a carrier.
60. (Currently Amended) A composition comprising the polypeptide fragment of claim 43 and a carrier.
61. (Cancelled).
62. (Re-presented formerly dependent claims 38-42) An epitope bearing fragment of the human NAF-1 polypeptide selected from the group consisting of:
- (a) an epitope bearing fragment consisting of at least amino acids 75 to 100 of SEQ ID NO:2;
  - (b) an epitope bearing fragment consisting of at least amino acids 168 to 180 of SEQ ID NO:2;
  - (c) an epitope bearing fragment consisting of at least amino acids 204 to 226 of SEQ ID NO:2;
  - (d) an epitope bearing fragment consisting of at least amino acids 258 to 281 of SEQ ID NO:2; and,
  - (e) an epitope bearing fragment consisting of at least amino acids 291 to 327 of SEQ ID NO:2.
63. (Re-presented formerly dependent claim 38) The epitope bearing fragment of claim 62 wherein said fragment is (a).
64. (Re-presented formerly dependent claim 39) The epitope bearing fragment of claim 62 wherein said fragment is (b).

65. (Re-presented formerly dependent claim 40) The epitope bearing fragment of claim 62 wherein said fragment is (c).

66. (Re-presented formerly dependent claim 41) The epitope bearing fragment of claim 62 wherein said fragment is (d).

67. (Re-presented formerly dependent claim 42) The epitope bearing fragment of claim 62 wherein said fragment is (e).